Liệu pháp chống ngưng tập tiểu cầu kép ở bệnh nhân hội chứng động mạch vành cấp: kéo dài bao lâu là đủ?
Tóm tắt
Liệu pháp chống ngưng tập tiểu cầu kép ở bệnh nhân hội chứng động mạch vành cấp: kéo dài bao lâu là đủ?
Tài liệu tham khảo
Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarc- tion: ISIS-2. ISIS-2 (second international study of infarct survival) collaborative group. Lancet 1988;2(8607): 349–60.
Yusuf S et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med. 2001;345(7):494–502.
Wiviott SD et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007;357(20):2001–15.
Wallentin L et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009;361(11):1045–57.
Wounter Jukema J et al. Antiplatelet therapy in patients with ST-elevation myocardial infarction undergoing myocardial revascularisation: beyond clopidogrel. Current Medical Research & Opinion 2012; Vol. 28, No. 2, 203–211.
Steinhubl SR et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA 2002;288(19):2411-20.
Valgimigli M et al. Prolong- ing Dual Antiplatelet Treatment After Grading Stent-Induced Intimal Hyperplasia Study (PRODIGY) Investigators. Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial. Circulation 2012;125:2015 – 2026.
Kim BK et al. RESET Investigators. A new strategy for discontinuation of dual antiplatelet therapy: the RESET Trial (Real Safety and Efficacy of 3-month dual antiplatelet Therapy following Endeavor zotarolimus-eluting stent implantation). J Am Coll Cardiol 2012;60:1340 – 1348.
Gwon HC et al. Six-month versus 12-month dual antiplatelet therapy after implant- ation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Re- duce Late Loss After Stenting (EXCELLENT) randomized, multicenter study. Circulation 2012;125:505–513.
Bhatt DL et al. CHARISMA Investigators. Patients with prior myocardial infarction, stroke, or symptomatic peripheral arter- ial disease in the CHARISMA trial. J Am Coll Cardiol 2007;49:1982–1988.
Mauri L et al. DAPT Study Investigators. Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. N Engl J Med 2014;371:2155 – 2166.
Bonaca MP et al. PEGASUS-TIMI 54 Steering Committee and Investiga- tors. Long-term use of ticagrelor in patients with prior myocardial infarction. N Engl J Med 2015;372:1791–1800.
Roe MT et al. TRILOGY ACS Investigators. Prasugrel versus clopido- grel for acute coronary syndromes without revascularization. N Engl J Med 2012; 367:1297 – 1309.
Morrow DA et al. TRA 2P–TIMI 50 Steering Commit- tee and Investigators. Vorapaxar in the secondary prevention of atherothrombotic events. N Engl J Med 2012;366:1404 –1413.
Udell JA et al. Long-term dual antiplatelet therapy for secondary prevention of cardiovascular events in the subgroup of patients with previous myocardial infarction: a collaborative meta- analysis of randomized trials. Eur Heart J. 2016;37:390-9.
Levine GN et al. 2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease. Circulation 2016;133:000–000, DOI: 10.1161/ CIR.0000000000000404.
Marco Roffi et al. 2015 ESC guidelines for the management of acute coronary syndrome in patients presenting without persistent ST-segment elevation. European Heart Journal. Doi: 10.1093/eurheartj/ ehv320.
Man-Fung Tsoi et al. Duration of dual antiplatelet therapy after drug-eluting stent implantation: Meta-analysis of large randomised controlled trials. Scientific Reports 2016; DOi: 10.1038/srep13204.
Abhishek Sharma et al. Duration of Dual Antiplatelet Therapy After Drug-Eluting Stent Implantation in Patients With and Without Acute Coronary Syndrome: A Systematic Review of Randomized Controlled Trials. Mayo Clin Proc. 2016;91(8):1084-1093.
Thomas W. Weiss et al. Expert position paper on prolonged dual antiplatelet therapy in secondary prevention following myocardial infarction. Wien Klin Wochenschr 2016; 128:450–457. DOI 10.1007/ s00508-016-1016-7.
